On Patientpower.eu, David Palacios, Head of Global Patient Relations, and Sanja Njegic, Head of Patient Advocacy & Relations in Europe at Novartis, explain how their company has moved from working with doctors and payers to working directly with patients. Show More Summary
Well, it is really hot. Really really hot. And I am moving kind of slow, as one should probably do in the summer. I didn’t even get to the Weekly Roundup last week, which means that some of what I … Continue reading ?
This morning I saw this tweet by a journalist: Talk about "Open Carry" in Ohio - This is "Open Nazism!" Any way, here's my response that I couldn't convert via Twitter: Read more »
Last week, the Centers for Medicare & Medicaid Services (CMS) released its latest forecasts for national health expenditures. See the Health Affairs article: National Health Expenditure Projections, 2015–25: Economy, Prices, And Aging Expected To Shape Spending And Enrollment. Show More Summary
The PLOS Medicine Editors announce a Special Issue on Dementia to be guest edited by Dr. Carol Brayne and Dr. Bruce Miller. Submissions are now being accepted ahead of the deadline of September 30. PLOS
"Data gives credibility, but stories provide truth," says Ash Rishi, Co-Founder and Managing Director of COUCH (read "Patient Storytelling Marketing"). Social media and patient stories are a "match made in heaven" and several pharmaShow More Summary
As reported in the trade media, GSK developed an iPhone app for use in "clinical research" (read "GSK Develops Rheumatoid Arthritis App for Clinical Trial Using Apple's ResearchKit"). It is claimed that this "[marks] the first time a...Show More Summary
PLOS Medicine Senior Research Editor Clare Garvey on week three of the Special Issue on Preventing Diabetes Read about week one Read about week two Week three of the PLOS Medicine Special Issue on Preventing Diabetes brings
Many 340B lobbyists frequently claim that the 340B Drug Pricing Program amounts to “only 2%” of total U.S. drug purchases and is therefore not a significant issue. This is an extremely careless misrepresentation of the truth. As I document below, 340B now accounts for at least 4% of the U.S. Show More Summary
CBI’s 4th Annual Coupon and Co-Pay Offer Design Optimization September 15-16, 2016 | Philadelphia, PA Exclusive Offer – Register by 8/12/2016 and save $500 (mention promo code COUPAF) Think coupon and co-pay programs are going away?Show More Summary
Today’s guest post comes from Kylanne Green, President and CEO of URAC. Kylanne shares an interesting perspective on the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). She explains how the transition from fee-for-service to value-based payment will impact various stakeholders, including pharmacists. Show More Summary
Serap Aksoy, co-Editor in Chief of PLOS NTDs and Marian Weidner, Senior Publications Assistant, give an overview of the recent International Writing Workshop As part of the journal’s outreach work, PLOS Neglected Tropical Diseases Editorial Board has
Poof! FB & SnapChat Offer #pharma Marketers Transient, Untraceable Messaging
Associate Editor Tom McBride discusses the new research and commentary appearing in the second week of PLOS Medicine’s Special Issue on Preventing Diabetes. Each week this July PLOS Medicine will be publishing new perspective and
Last week, Walgreens Boots Alliance (WBA) provided a small but notable boost to Valeant Pharmaceuticals. WBA co-COO Alex Gourlay said that the company was “satisfied” with its Valeant relationship. That’s no surprise, given the favorable economics for Walgreens. Show More Summary
What do FDA press releases for the year say about the rate of new approvals for 2016? Periodically I take a look at what FDA has said – and a little bit conversely at what it hasn’t. In April, I … Continue reading ?